ライフサイエンスコーパス: deoxycholic acid

1 linked to the rigid skeleton of the natural deoxycholic acid.

2 s as well as by efficient rehydroxylation of deoxycholic acid.

3 en the two porins, namely the sensitivity to deoxycholic acid.

4 hypersensitive to the anionic bile detergent deoxycholic acid.

5 ed with cholylglycine, 7-oxocholic acid, and deoxycholic acid.

6 holic acid, 45%; chenodeoxycholic acid, 43%; deoxycholic acid, 11%, and lithocholic acid, 1%.

7 tly higher concentrations of tumor-promoting deoxycholic acid (26.7 +/- 4.2 compared with 11 +/- 1.9

8 cholic acid, 85%; chenodeoxycholic acid, 7%; deoxycholic acid, 3%; allocholic acid, 3%; and unidentif

9 Instead of deoxycholic acid, 3alpha,6beta,12alpha-trihydroxycholani

10 P < .05), cholic acid (-72%, P < .005), and deoxycholic acid (-62%, P < .05).

11 ic gut microbiome-derived BAs, such as 7-oxo-deoxycholic acid (7-oxo-DCA) and isodeoxycholic acid (is

12 indole-3-lactic acid and decreased levels of deoxycholic acid, a pro-inflammatory secondary bile acid

13 Deoxycholic acid, a strong detergent, greatly enhanced t

14 sed intratesticular BA levels in general and deoxycholic acid, a TGR5 agonist, in particular.

15 The results are interpreted as deoxycholic acid acting as an open-channel blocker, whic

16 chenodeoxycholic acid, lithocholic acid, and deoxycholic acid activated the farnesoid X receptor (FXR

17 he liver after mice were given injections of deoxycholic acid and an increase after they were fed fen

18 ically embedded logic circuits incorporating deoxycholic acid and anhydrotetracycline sensors.

19 environment-specific manner to the inducers (deoxycholic acid and anhydrotetracycline) of the genetic

20 Consistently, serum deoxycholic acid and lithocholic acid (FXR antagonists)

21 ity, the resultant elevation of unconjugated deoxycholic acid and lithocholic acid activates the G-pr

22 and decreased concentrations of secondary BA deoxycholic acid and lithocholic acid, indicating reduce

23 gher levels of secondary bile acids, such as deoxycholic acid and lithocholic acid, than those fed th

24 suggests that the active form is the neutral deoxycholic acid and not the negatively charged species.

25 ose tissue, such as the bile acid derivative deoxycholic acid and the microbiome-derived tryptophan m

26 Bile acids deoxycholic acid and ursodeoxycholic acid differentially

27 ndary BAs, including lithocholic acid (LCA), deoxycholic acid, and 3-oxoLCA, significantly improved p

28 re properties, such as conductance, block by deoxycholic acid, and sensitivity to acidic pH.

29 brane sensitizes cells to the bile component deoxycholic acid, and the repression of OmpT in the inte

30 eased 12alpha-hydroxylated BAs (cholic acid, deoxycholic acid, and their conjugated forms).

31 d the bile acid metabolites taurocholate and deoxycholic acid as direct A. muciniphila-derived molecu

32 database and identify a secondary bile acid, deoxycholic acid, as a potential therapeutic component.

33 derived metabolite, the secondary bile acid deoxycholic acid, can restore pDC- and MyD88-dependent t

34 The addition of an individual bile acid (deoxycholic acid, chenodeoxycholic acid, ursodeoxycholic

35 Total SBA, lithocholic acid, and deoxycholic acid concentrations were negatively correlat

36 d that altered levels of ursodeoxycholic and deoxycholic acid conjugates were linked to islet autoimm

37 bile acids of microbial origin derived from deoxycholic acid (DCA) (glycodeoxycholate, 7-ketodeoxych

38 p-1/WAF1/mda6 (p21) enhanced the toxicity of deoxycholic acid (DCA) + MEK1/2 inhibitor.

39 In this study, the mechanism(s) by which deoxycholic acid (DCA) activates the JNK pathway were ex

40 We investigated the roles of hydrophobic deoxycholic acid (DCA) and hydrophilic ursocholic acid (

41 ant metabolites are the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), which

42 to test this by investigating the effects of deoxycholic acid (DCA) and ursodeoxycholic acid on the e

43 Secondary bile acids like deoxycholic acid (DCA) are well-established tumor promot

44 e identified ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) as the two most potent inhibitors

45 Deoxycholic acid (DCA) caused prolonged activation of th

46 Deoxycholic acid (DCA) is an endogenous secondary bile a

47 Secondary bile acids (BA) such as deoxycholic acid (DCA) promote the development of severa

48 tudies have demonstrated in hepatocytes that deoxycholic acid (DCA) promotes inactivation of protein

49 tio of dihomo-gamma-linolenic acid (DGLA) to deoxycholic acid (DCA) species (DCAS) was significantly

50 CpMRP1 binds bacterial metabolites, notably deoxycholic acid (DCA) that inhibits C. parvum growth.

51 rts cholic acid into the secondary bile acid deoxycholic acid (DCA) very efficiently even though the

52 Deoxycholic acid (DCA) was instilled into the rat colon

53 Deoxycholic acid (DCA) was the best activator of ERK (3.

54 bile acids enhanced DR5/TRAIL-R2 expression, deoxycholic acid (DCA) was the most potent.

55 )/FXR, only chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA) were able to stimulate a heterolo

56 henodeoxycholic acid (CDCA) and secondary BA deoxycholic acid (DCA) were measured following MDMA (20

57 deficiency, with significant upregulation of deoxycholic acid (DCA), a carcinogenic bile acid.

58 Second, CDCA, deoxycholic acid (DCA), and other synthetic FXR agonists

59 Concentrations of the secondary bile acid, deoxycholic acid (DCA), are aberrantly elevated in color

60 Secondary bile acids, particularly deoxycholic acid (DCA), are implicated in promoting colo

61 a) determine if UDCA inhibits apoptosis from deoxycholic acid (DCA), as well as from ethanol, TGF-bet

62 l metabolic byproduct of secondary bile acid deoxycholic acid (DCA), at as low as 50 uM, inhibited 82

63 Treatment of hepatocytes with deoxycholic acid (DCA), chenodeoxycholic acid (CDCA) or

64 Deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), ta

65 CA, CDCA, and deoxycholic acid (DCA), fed as a supplement to the diet,

66 , CP-C and CP-A, to the oncogenic bile acid, deoxycholic acid (DCA), for 1 year.

67 ransit, and an increase in the proportion of deoxycholic acid (DCA), have been implicated in the path

68 g tauro-beta-muricholic acid (T-betaMCA) and deoxycholic acid (DCA), induce proliferation and DNA dam

69 Microbiota-derived BA metabolites such as deoxycholic acid (DCA), lithocholic acid (LCA), and urso

70 BAs (deoxycholic acid (DCA), taurolithocholic acid) and the s

71 ing with methyl-beta-cyclodextrin suppressed deoxycholic acid (DCA)-induced apoptosis, and staining f

72 Previously, we demonstrated that deoxycholic acid (DCA)-induced ERK1/2 and AKT signaling

73 Previously, we have demonstrated that deoxycholic acid (DCA)-induced signaling of extracellula

74 Moreover, Jag1/2 deficiency exacerbates the deoxycholic acid (DCA)-induced squamous epithelial injur

75 (AP-1) transcription factor was crucial for deoxycholic acid (DCA)-mediated GADD153 gene transcripti

76 with a preference for glycine-conjugates and deoxycholic acid (DCA).

77 use fecal secondary bile acids [particularly deoxycholic acid (DCA)] are considered to promote format

78 hepatocytes exposed to low concentrations of deoxycholic acid (DCA, 50 microM).

79 ure of hX4-Gq in a complex with 3-phosphated deoxycholic acid (DCA-3P), a mimic of the endogenous 3-s

80 CA-3P), a mimic of the endogenous 3-sulfated deoxycholic acid (DCA-3S).

81 Bile acids (deoxycholic acid, DCA; taurocholic acid, TCA) activated

82 th the highly chaotropic bile salt detergent deoxycholic acid demonstrated that some Bdr paralogs may

83 mpounds was demonstrated by preparation of a deoxycholic acid derivative.

84 id, 1-hydroxy-2-naphthoic acid, cholic acid, deoxycholic acid, dioctylsulfosuccinic acid, and pamoic

85 completed a total synthesis of enantiomeric deoxycholic acid (ent-DCA) from achiral 2-methyl-1,3-cyc

86 -LCA), chenodeoxycholic acid (ent-CDCA), and deoxycholic acid (ent-DCA) to induce toxicity and apopto

87 neurological decline, whereas cholic acid or deoxycholic acid feeding worsened AOM-induced neurologic

88 on in vitro assays with substrate preference deoxycholic acid > chenodeoxycholic acid > cholic acid >

89 Treatment of serum with 0.5% deoxycholic acid in the absence of salt produced HCV wit

90 n with hyperphagia, while direct infusion of deoxycholic acid in the NTS of HF rats activated TGR5 to

91 eding-induced rise of endogenous TGR5 ligand deoxycholic acid in the plasma and subsequently in the N

92 s of cholic acid, chenodeoxycholic acid, and deoxycholic acid in their conjugated (glycine and taurin

93 the effects of chenodeoxycholic, cholic, and deoxycholic acid in unconjugated (CDCA, CA, and DCA) and

94 In wild-type hepatic macrophages, deoxycholic acid induced the association of Gal3 and NLR

95 Deoxycholic acid inhibited contractility of colonic long

96 idium spp. increased the secondary bile acid deoxycholic acid levels in the ileum, which in turn inhi

97 ization analyses showed genetically elevated deoxycholic acid levels were causally associated with hi

98 ugated with seven taurocholic and tetrameric deoxycholic acids (LHTD4).

99 Application of deoxycholic acid, lithocholic acid, or oleanolic acid (a

100 siRAGE) was delivered to myocardium by using deoxycholic acid-modified polyethylenimine (PEI-DA) as a

101 have reduced levels of lithocholic acid and deoxycholic acid (normally the most abundant gut SBAs),

102 iated with HCV after treatment of serum with deoxycholic acid or NP-40, whereas ApoE was removed from

103 icant changes were detected for cholic acid, deoxycholic acid, or chenodeoxycholic acid.

104 sed with increasing temperature, addition of deoxycholic acid, or treatment with heparinase I.

105 an open-channel blocker, which may relate to deoxycholic acid permeation.

106 Xhosa individuals had higher fecal levels of deoxycholic acid, shown to be associated with higher CRC

107 The ratio of dihomo-gamma-linolenic acid to deoxycholic acid species is a potential biomarker for th

108 brella conjugates, derived from cholic acid, deoxycholic acid, spermidine, lysine, and 5-mercapto-2-n

109 Lithocholic acid and deoxycholic acid, the principal ligands for TGR5, are de

110 HK-2 cells were treated with deoxycholic acid to establish a renal tubular epithelial

111 d with cholesterol, sitosterol, cholic acid, deoxycholic acid, ursodeoxycholic acid, cholestyramine,

112 etergents such as sodium dodecyl sulfate and deoxycholic acid were inhibitory.

113 ts low affinity for common bile acids except deoxycholic acid, which uniquely lacks a 7alpha-hydroxyl